Evolent Health Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Evolent Health wird ein jährliches Gewinn- und Umsatzwachstum von 79% bzw. 13.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 79% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.6% betragen.
Wichtige Informationen
79.0%
Wachstumsrate der Gewinne
79.0%
EPS-Wachstumsrate
| Healthcare Services Gewinnwachstum | 30.6% |
| Wachstumsrate der Einnahmen | 13.7% |
| Zukünftige Eigenkapitalrendite | 8.6% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Evolent Health: A Shot At Revival After Market Bruising
Nov 12Take Care Before Jumping Onto Evolent Health, Inc. (NYSE:EVH) Even Though It's 49% Cheaper
Nov 09
We Like These Underlying Return On Capital Trends At Evolent Health (NYSE:EVH)
Nov 07Evolent Health (NYSE:EVH) Has A Pretty Healthy Balance Sheet
Sep 19Evolent Health: Let The Bidding Begin
Aug 23Potential Upside For Evolent Health, Inc. (NYSE:EVH) Not Without Risk
Jul 29Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher
Jul 01Evolent Health: Recent Pullback, A Buying Opportunity Or Not? (Rating Downgrade)
May 22These 4 Measures Indicate That Evolent Health (NYSE:EVH) Is Using Debt Reasonably Well
May 05Evolent Health, Inc. (NYSE:EVH) Doing What It Can To Lift Shares
Apr 08Evolent Health (NYSE:EVH) Is Experiencing Growth In Returns On Capital
Mar 12Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt
Jan 17Many Still Looking Away From Evolent Health, Inc. (NYSE:EVH)
Dec 21Evolent Health (NYSE:EVH) Is Looking To Continue Growing Its Returns On Capital
Nov 30A First Evaluation On Evolent Health
Oct 04Does Evolent Health (NYSE:EVH) Have A Healthy Balance Sheet?
Sep 29There's Been No Shortage Of Growth Recently For Evolent Health's (NYSE:EVH) Returns On Capital
Sep 01An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 47% Undervalued
Aug 04Evolent Health: Business Economics Still Appealing, Reiterate Buy
Jul 19Cautious Investors Not Rewarding Evolent Health, Inc.'s (NYSE:EVH) Performance Completely
Jun 14Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt
May 30An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 34% Undervalued
May 02Evolent Health (NYSE:EVH) Shareholders Will Want The ROCE Trajectory To Continue
Apr 17Evolent Health GAAP EPS of $0.11 beats by $0.13, revenue of $382.4M beats by $9.47M
Feb 22Is Evolent Health (NYSE:EVH) A Risky Investment?
Feb 19Evolent Health: Strengthening Fundamentals, Investing At High Rates Of Return
Feb 15Is Evolent Health, Inc. (NYSE:EVH) Potentially Undervalued?
Feb 01Evolent Health (NYSE:EVH) Might Have The Makings Of A Multi-Bagger
Jan 14Evolent spikes as Humana partnership expands
Jan 12Is Evolent Health, Inc. (NYSE:EVH) Trading At A 49% Discount?
Dec 27Evolent Health offered $23.5M class action securities settlement
Sep 19Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher
Sep 18Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 3,356 | 55 | 223 | 223 | 11 |
| 12/31/2025 | 2,935 | 5 | 188 | 180 | 15 |
| 12/31/2024 | 2,560 | -81 | 0 | 52 | 14 |
| 9/30/2024 | 2,464 | -104 | 93 | 134 | N/A |
| 6/30/2024 | 2,354 | -106 | 145 | 176 | N/A |
| 3/31/2024 | 2,176 | -141 | 129 | 155 | N/A |
| 12/31/2023 | 1,964 | -142 | 114 | 143 | N/A |
| 9/30/2023 | 1,790 | -112 | 55 | 89 | N/A |
| 6/30/2023 | 1,632 | -77 | -21 | 25 | N/A |
| 3/31/2023 | 1,483 | -40 | -10 | 38 | N/A |
| 12/31/2022 | 1,352 | -19 | -59 | -12 | N/A |
| 9/30/2022 | 1,218 | -4 | -25 | 19 | N/A |
| 6/30/2022 | 1,088 | -19 | 35 | 67 | N/A |
| 3/31/2022 | 990 | -24 | 1 | 29 | N/A |
| 12/31/2021 | 908 | -30 | 11 | 39 | N/A |
| 9/30/2021 | 906 | -45 | -67 | -41 | N/A |
| 6/30/2021 | 923 | -68 | -131 | -106 | N/A |
| 3/31/2021 | 918 | -261 | -74 | -44 | N/A |
| 12/31/2020 | 925 | -328 | -48 | -16 | N/A |
| 9/30/2020 | 915 | -515 | -25 | 10 | N/A |
| 6/30/2020 | 895 | -504 | -26 | 14 | N/A |
| 3/31/2020 | 870 | -334 | -76 | -37 | N/A |
| 12/31/2019 | 687 | -304 | -87 | -43 | N/A |
| 9/30/2019 | 803 | -121 | -126 | -81 | N/A |
| 6/30/2019 | 733 | -107 | -85 | -42 | N/A |
| 3/31/2019 | 685 | -86 | -67 | -22 | N/A |
| 12/31/2018 | 627 | -53 | -190 | -21 | N/A |
| 9/30/2018 | 548 | -49 | -27 | 10 | N/A |
| 6/30/2018 | 506 | -49 | N/A | -8 | N/A |
| 3/31/2018 | 468 | -56 | N/A | -18 | N/A |
| 12/31/2017 | 435 | -61 | N/A | -28 | N/A |
| 9/30/2017 | 409 | -65 | N/A | -55 | N/A |
| 6/30/2017 | 362 | -64 | N/A | -51 | N/A |
| 3/31/2017 | 311 | -55 | N/A | -49 | N/A |
| 12/31/2016 | 254 | -160 | N/A | -36 | N/A |
| 9/30/2016 | 212 | -146 | N/A | -20 | N/A |
| 6/30/2016 | 192 | -147 | N/A | -35 | N/A |
| 3/31/2016 | 146 | 220 | N/A | -39 | N/A |
| 12/31/2015 | 97 | 330 | N/A | -18 | N/A |
| 9/30/2015 | 51 | 322 | N/A | -12 | N/A |
| 6/30/2015 | 10 | 329 | N/A | -6 | N/A |
| 3/31/2015 | N/A | -37 | N/A | 4 | N/A |
| 12/31/2014 | N/A | -31 | N/A | N/A | N/A |
| 9/30/2014 | 13 | -29 | N/A | -9 | N/A |
| 12/31/2013 | 26 | 2 | N/A | -14 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EVH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.6%).
Ertrag vs. Markt: EVH wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: EVH wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: EVHDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: EVHDie Einnahmen des Unternehmens (13.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: EVHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.6%).